Mefloquine side effects can last anywhere from a few days to several years after stopping the drug, and in some cases, the FDA warns they can be permanent. The timeline depends heavily on which side effects you’re experiencing. Common symptoms like nausea or headache typically clear within weeks, but neurological and psychiatric effects, particularly dizziness, balance problems, and ringing in the ears, can persist for months or years.
Why Mefloquine Stays in Your Body So Long
Mefloquine has an unusually long elimination half-life, averaging about 3 weeks, with a range of 2 to 4 weeks in healthy adults. That means it takes roughly 3 months after your last dose for most of the drug to clear your bloodstream, and even longer to fully leave your system. Most medications clear in hours or days, so mefloquine is an outlier.
The drug also accumulates in body tissues, including the brain. Postmortem examinations of U.S. military personnel who took mefloquine for malaria prevention found significant concentrations of the drug in brain tissue. This tissue accumulation helps explain why some side effects persist well beyond what the drug’s blood levels would predict.
Mild Side Effects: Days to Weeks
The more common, less serious side effects of mefloquine, things like nausea, vomiting, diarrhea, headache, and general fatigue, tend to resolve relatively quickly. One study found that people who took mefloquine as a short treatment course had a median side effect duration of about 4 days. Those who took it as long-term prophylaxis (a weekly dose over months) had a longer median duration of around 16 days, even though they received a lower total dose. This suggests that repeated weekly exposure, rather than just the total amount taken, plays a role in how long you feel side effects.
Neurological Symptoms: Months to Years
Balance problems, dizziness, vertigo, and ringing in the ears (tinnitus) are the neurological side effects that cause the most concern. The FDA updated mefloquine’s label specifically to warn that these vestibular symptoms can last months to years after the drug is stopped, or become permanent. In many reported cases, these problems started early, sometimes after just one or two doses.
A case report published in Drug Safety detailed a military service member whose balance problems began within two months of starting mefloquine. Four and a half years after his initial exposure, he was still experiencing multiple episodes of vertigo per week severe enough to force him to lie down. He had a constant sensation of internal spinning that worsened with position changes or physical activity, and he had fallen multiple times while walking. His symptoms showed little to no improvement over that entire period.
This is not the typical outcome, but it illustrates the upper end of what’s possible. The FDA now explicitly warns about the possibility of permanent vestibular damage.
Psychiatric Symptoms: Highly Variable
Mefloquine can cause anxiety, depression, restlessness, confusion, vivid dreams, nightmares, and in rare cases, hallucinations or psychosis. These psychiatric symptoms are among the drug’s most well-known risks and prompted the FDA to require a boxed warning on the label.
Vivid dreams and nightmares are particularly common. In one study, 21% of people who reported nightmares while taking mefloquine said these continued for 3 years or longer after stopping the drug. International drug regulators once assumed sleep disturbances would resolve after discontinuation, but that assumption has been revised. Current warnings acknowledge that these symptoms may persist for years.
Other psychiatric effects like anxiety and depression follow a similar pattern. For many people they fade within weeks to months, but a subset of users reports symptoms that linger far longer. The FDA’s guidance states that the appearance of any psychiatric symptom during prophylactic use, including acute anxiety, depression, restlessness, or confusion, signals a risk for more serious problems, and the drug should be stopped immediately.
Recognizing Persistent Symptoms
The cluster of long-lasting symptoms that some people experience after mefloquine exposure tends to include several overlapping problems: dizziness or vertigo, poor short-term memory, emotional instability, vivid or disturbing dreams, anxiety, and difficulty with balance and coordination. In the military case mentioned above, the service member’s symptoms progressed over four years to include significant short-term memory problems requiring speech therapy to assist with daily activities.
These symptoms can be tricky to connect back to mefloquine, especially if months or years have passed since you took it. The drug’s long half-life and tissue accumulation mean that the onset of new symptoms can be delayed, and symptoms that began during treatment can quietly worsen over time rather than improving.
What Affects How Long Side Effects Last
There’s no reliable way to predict who will experience lasting effects, but a few factors appear to matter. The duration of exposure plays a role: people who take mefloquine weekly for months as malaria prophylaxis tend to report longer-lasting side effects than those who take a short treatment course, even when the treatment course involves a higher total dose. This points to cumulative exposure as a key factor.
Early symptoms also serve as a warning. The FDA notes that many cases of lasting neurological damage involved people who developed symptoms early in treatment but continued taking the drug. Stopping mefloquine at the first sign of dizziness, balance problems, anxiety, or vivid dreams may reduce the risk of persistent effects, though it cannot eliminate that risk entirely since some problems have developed after just one or two doses.
If you’re still experiencing dizziness, balance issues, tinnitus, memory problems, or psychiatric symptoms weeks after your last dose, these are not necessarily going to resolve on their own with time. Vestibular testing and neuropsychiatric evaluation can help determine whether there’s been lasting damage and guide management of symptoms that remain.